Noticias de FATE_US

Noticias del mercado

Últimas noticias sobre FATE_US — 209 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: FATE_US ✕ 209 resultados

11/05/2026 FATE_US — ChartMill

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

11/05/2026 FATE_US — GlobeNewswire ES ← EN

Fate Therapeutics muestra la actividad clínica de FT819 en el LES

El tratamiento de dosis única de FT819 sin quimioterapia condicionante logra el estado de baja actividad de la enfermedad del lupus (LLDAS) en pacientes con LES activo; célula B duradera...

11/05/2026 FATE_US — GlobeNewswire ES ← EN

Fate Therapeutics muestra la actividad clínica de FT819 en el LES

El tratamiento de dosis única de FT819 sin quimioterapia condicionante logra el estado de baja actividad de la enfermedad del lupus (LLDAS) en pacientes con LES activo; célula B duradera...

11/05/2026 FATE_US — Investing.com

Fate Therapeutics presents CAR T-cell therapy data at ASGCT

11/05/2026 FATE_US — Investing.com

Fate Therapeutics presents CAR T-cell therapy data at ASGCT By Investing.com

11/05/2026 FATE_US — Yahoo Finance

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

11/05/2026 FATE_US — Investing.com

Fate Therapeutics presents CAR T-cell therapy data at ASGCT By Investing.com

11/05/2026 FATE_US — Stock Titan

Single-dose lupus therapy shows responses without conditioning chemo

11/05/2026 FATE_US — The Manila Times

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

11/05/2026 FATE_US — GlobeNewswire

Fate Therapeutics Showcases FT819 Clinical Activity in SLE

11/05/2026 FATE_US — The Manila Times

Fate Therapeutics Showcases FT819 Clinical Activity in SLE without the use of Conditioning Chemotherapy at the 2026 ASGCT Annual Meeting

11/05/2026 FATE_US — Investing.com

Fate Therapeutics presents CAR T-cell therapy data at ASGCT By Investing.com

09/05/2026 FATE_US — TradingView

Number of shareholders of Fate Therapeutics, Inc. – NASDAQ:FATE

Número de accionistas, estadísticas trimestrales y anuales de Fate Therapeutics, Inc..

08/05/2026 FATE_US — Meyka ES ← EN

Acciones de FATE: la oficial Cindy Tahl adquiere 44,444 acciones 08 de mayo de 2026

Cindy Tahl, directora de Fate Therapeutics, adquirió 44.444 acciones a 1,05 dólares por acción el 6 de mayo de 2026. Señal de compra interna para las acciones de FATE.

07/05/2026 FATE_US — Gotrade ES ← EN

Precio de las acciones de Fate Therapeutics Inc (FATE) hoy y análisis

Fate Therapeutics Inc (FATE) Stock Price Today & Analysis

07/05/2026 FATE_US — Stocktwits

Fate Therapeutics Inc (FATE) News, Articles, Events & Latest Updates

07/05/2026 FATE_US — Stock Titan

Fate Therapeutics (FATE) officer exercises 166,664 options, holds 609k shares

06/05/2026 FATE_US — newser.com

What Fate Therapeutics (FATE) is doing that smart investors recognize (Weakens) 2026-05-06 - Institutional Buying

06/05/2026 FATE_US — newsline.com

What Fate Therapeutics (FATE) is doing that smart investors recognize (Weakens) 2026-05-06 - Stop Hunt

06/05/2026 FATE_US — MSN